RxDoctor Payments Data

Uyen Dinh

Psychiatric/Mental Health · Pittsburg, KSNPI 1568870145

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $12,513 of the $19,954 with a category attached, or 62.7%. AbbVie accounts for 73.5% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2023 at $12,890 and has fallen 88.4% since, to $1,491 in 2025. Among psychiatric/mental health clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$19,954in general payments, 2019–2025

Across 187 payments — averaging $106.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$15K
  • Alkermes, Inc.$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • Otsuka America Pharmaceutical, Inc.$923
  • Johnson & Johnson$870
  • Axsome Therapeutics, Inc.$390
  • plus $1K from 13 others

What the payments were for

  • Speaking & faculty fees$12,51363%
  • Travel & lodging$1,4978%
  • Food & beverage$5,89430%
  • Education$510%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,954 in reported general payments places this provider in the 95th percentile of 404 psychiatric/mental health providers in Kansas.

See all psychiatric/mental health providers in Kansas

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl58$86,387
LybalviOlanzapine/Samidorphan Malate34$59,447
Invega SustennaPaliperidone Palmitate16$52,486
Abilify MaintenaAripiprazole11$23,982
RexultiBrexpiprazole13$19,685
Lurasidone Hcl59$15,219
Paliperidone ErPaliperidone53$15,055
TrintellixVortioxetine Hydrobromide23$12,259
BelsomraSuvorexant27$12,025
FetzimaLevomilnacipran Hcl15$8,165
Chlorpromazine Hcl12$7,395
Perphenazine12$5,964
Desvenlafaxine Succinate ErDesvenlafaxine Succinate37$3,438
Clozapine22$3,304
Oxcarbazepine51$2,781

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar, Fetzima$14,671$94,55373 claims
Alkermes, Inc.Lybalvi$1,032$59,44734 claims
Johnson & JohnsonInvega Sustenna$870$52,48616 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$923$43,66724 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$72$12,25923 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 404 psychiatric/mental health providers in Kansas.

Other psychiatric/mental health in Pittsburg

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →